All News

Scanxiety, fear of recurrence, whatever you choose to call it, it is real. A sleepless night or hard time here and there doesn't mean you aren't dealing with it well, it means you are human.

Three storytellers offered their experiences with BRCA mutation at a Basser Center for BRCA event in New York City.

Grant to Be Funded by the V Foundation to Early Career Investigator at The University of Kansas Cancer Center

The V Foundation for Cancer Research and Parker Institute for Cancer Immunotherapy Join as Sponsors

Finding a mentor during treatment, or becoming one into survivorship can prove to be very helpful.

Traveling internationally has its challenges, but for those with prosthetics, it's a little more complicated.

These four lessons about what comes after cancer are truly powerful.

Can providers decrease opioid prescriptions after surgery, while still managing care adequately?

The Food and Drug Administration has granted a priority review to a new drug application for selinexor (KPT-330) for the treatment of patients with penta-refractory multiple myeloma.

Long-term opioid use is more prevalent among patients treated with invasive surgical techniques for early-stage non-small cell lung cancer than those who undergo minimally-invasive surgery.

The Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), according to Merck, the manufacturer of the HPV vaccine.

I didn’t really like this surgeon very much. She was so young and soft spoken.

Immunotherapy has been a buzzworthy topic in the field of bladder cancer over the last couple of years. However, according to a Food and Drug Administration (FDA) safety warning, patients with metastatic disease may need to have their treatment altered.

October is a great month to support male breast cancer, too.

Non-pharmacologic integrative medicine approaches such as aromatherapy and reflexology can dramatically reduce the pain and anxiety associated with cervical radiation therapy, according to a clinical study currently underway at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

Sometimes that product or campaign does good, but sometimes it doesn't. Here's how to sort through the pink marketing

For many cancer survivors, the thought of returning to their cancer clinic after treatment ends may be off-putting, as it could bring up difficult memories. But Arleen Weitz could not wait to get back into the infusion center at the Sidney Kimmel Cancer Center (SKCC), Jefferson Health to do some good.

There are dozens of potential side effects, and more are being reported every month.

Viral germs pose a concerned health risk for those with a compromised immune system.

Patients with cancer are 10 times less likely to have an opioid-associated death, according to recent research conducted at Duke University.

The FDA has granted the PARP inhibitor Rubraca (rucaparib) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least one androgen receptor–directed therapy and taxane-based chemotherapy.

Fighting cancer is hard, but fighting it when you have to bring your kids along for the ride makes it even harder.

Pinktober heralds the arrival of so much pink that some of us run screaming from the sight of it, despite the good intentions of Breast Cancer Awareness Month. As I explain how I have made my peace with pink, you might feel better about your own choices.

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

A breast cancer patient's go-to resources for starting and continuing the cancer talk with your kids

Here are the top 5 CURE stories for September 2018.

Here are a few tips how to get the ball rolling on advocating for new legislation to help improve care.

The Food and Drug Admnistration has approved a once-weekly dosing option of Kyprolis (carfilzomib) to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.